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Abstract
Electroconvulsive therapy (ECT) may be considered for treatment of severe, treatment-resistant, and
emergent depression associated with MDD or bipolar disorder. Patients with epilepsy usually take
medications that raise the seizure threshold, which poses challenges during ECT. We report a 66-year-old
male with epilepsy taking levetiracetam extended-release (XR), lorazepam, and zonisamide requiring ECT for
severe MDD. After literature review, the XR form of levetiracetam was changed to higher doses of the
immediate-release (IR) formulation, and zonisamide was discontinued 2 days prior to ECT in the hospital
and was resumed when the patient underwent outpatient continuation ECT. The patient was treated to
remission after receiving 8 acute bilateral ECT treatments before being transitioned to continuation ECT. We
provide a brief review of medication management of antiepileptic drugs and other medications that increase
the seizure threshold during ECT. To our knowledge, this is the first reported case describing the
management of levetiracetam, lorazepam, and zonisamide concomitantly during ECT. Our case suggests
that utilizing the IR formulation of levetiracetam, administering the evening dose early the day prior to the
procedure, and temporarily discontinuing zonisamide prior to bilateral ECT is effective for the treatment of
severe MDD while maintaining seizure prophylaxis.
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Background
Most treatment guidelines support the use of electrocon-
vulsive therapy (ECT) in severe, treatment-resistant, or
emergent cases of MDD.1,2 The neuronal mechanism of
ECT seen in MDD is unclear with the main theory being
that seizures induce changes in neurotransmitters, neuro-
plasticity, and brain tissue connectivity.1,3 Patients with
epilepsy requiring ECT likely receive seizure threshold–
raising medications, such as benzodiazepines (BZDs) or
antiepileptic drugs (AEDs). The goal of medication
management in such cases is to achieve adequate seizure
(eg, 30 to 90 seconds) during ECT without causing
spontaneous seizures.4,5 ECT is often delivered using brief
pulse width and electrical intensity and titrated based on
minimum intensity to exceed the seizure threshold.1
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Because BZDs and AEDs may diminish ECT response,
considerations can be made to alter the anesthetic
regimen prior to ECT, use flumazenil prior to ECT in
patients using BZDs, and decrease or withhold the
evening and/or morning doses of seizure threshold–
increasing medications prior to ECT.5 Contradictory to
this, studies have shown unilateral, bifrontal, or bitempo-
ral ECT to be effective in patients with primarily
nonepileptic mood disorders taking AEDs,6-8 and BZDs
may not negatively affect ECT outcomes in patients with
depression.3 In patients with seizure disorders undergoing
ECT, it has been suggested to continue AEDs with
neurology consultation and, in the event of medication
alterations, return AEDs to previously prescribed doses
after ECT is concluded.4 To our knowledge, we report the
first patient with MDD and a seizure disorder managed
with bilateral ECT who was taking levetiracetam, loraze-
pam, and zonisamide.
Case Report
Our patient is a 66-year-old male with MDD with
psychotic features, unspecified anxiety disorder, and
generalized tonic-clonic seizures admitted to the psychi-
atric hospital with suicidal thoughts. He presented with
profound psychomotor retardation, cognitive latency,
thought blocking, anorexia with weight loss, and difficulty
with sleep maintenance. The patient also had nihilistic-
type delusions that he was already dead or imminently
dying. The patient had been seizure-free with no AED
changes for at least 1 year. Medications at admission
included fluoxetine 20 mg daily, levetiracetam 750 mg
extended-release (XR) nightly, lorazepam 1 mg every
morning and 2 mg every evening, and zonisamide 300 mg
nightly. He initiated fluoxetine and lorazepam within the
preceding month. Previous trials of escitalopram and
quetiapine were not effective; mirtazapine was briefly
effective. Fluoxetine and lorazepam were discontinued on
the day of admission due to ineffectiveness and the
possibility of worsening cognitive dysfunction, respective-
ly. Oral venlafaxine 75 mg daily and mirtazapine 15 mg
nightly were initiated on admission with considerations to
start ECT if ineffective. Two days later, he began to refuse
all medications and required assistance eating. On the
third evening, he had an approximate 60-second seizure,
which required transfer to the emergency department and
treatment with IV levetiracetam and lorazepam and oral
zonisamide. Lorazepam was continued IV at 0.5 mg 4
times daily on day 4, which improved his ability to take
medications and make decisions. It was determined that
ECT would be appropriate, but the patient was not ready
to consent. Nonetheless, pharmacotherapy was modified
in order to prepare for ECT. After literature review and
discussion with neurology, levetiracetam was switched to
1000 mg immediate-release (IR) twice daily with the
evening dose to be given at 2 pm the night prior to ECT
while holding the morning dose on the day of ECT.
Lorazepam was reduced to 0.25 mg 4 times daily on the
seventh day of hospitalization and discontinued on the
ninth day. Zonisamide was tapered and discontinued 2
days prior to the first ECT session and withheld during the
remainder of hospitalization. The patient was observed to
have a limited-duration seizure 2 days prior to initial ECT
that may have been related to downward taper of AEDs.
After deliberation, the patient agreed to ECT, and the
acute series was initiated on day 12 for a total of 8
sessions (Table). ECT was administered with the Thyma-
tron System IV (Somatics, LLC, Venice, FL) with a pulse
width of 0.5 ms, 30 Hz, 40 joules, and duration of 7.5
seconds. Methohexital was the anesthesia-inducing agent
used. Adequate seizure activity was seen (Table). He
restarted oral lorazepam 0.5 mg twice daily after the first
ECT for continued neurovegatative symptoms while
holding the nightly dose prior to ECT. After the second
ECT, improvements were robust across all domains of
prior dysfunction; the patient was engaging socially,
smiling, eating, and sleeping; mood was much improved,
and delusions resolved. Following the fourth ECT,
lorazepam was no longer indicated and discontinued.
The patient discharged home after the fifth ECT,
completed 8 acute treatments, and received continuation
ECT following this. Following the acute ECT series, the
patient resumed zonisamide and levetiracetam XR at
previously prescribed doses. The patient held these AEDs
4 days prior to each continuation ECT and utilized twice
daily levetiracetam 1000 mg IR monotherapy with the last
dose at least 24 hours before ECT. Nights following
continuation ECT, zonisamide and levetiracetam XR were
TABLE: Electrode placement and seizure duration during electroconvulsive therapy (ECT) course
Treatment No. 1 2 3 4 5 6 7 8 9 10 11 12
Days since ECT initiation 0 2 5 7 9 12 14 16 30 44 65 100
Electrode placement BT BT BT BF BT BT BT BT RUL BT BT BT
Seizure duration, s
Motor 28 39 28 32 27 25 24 24 16 30 21 38
EEG 51 63 51 48 53 51 42 38 39 64 48 68
BF¼ bifrontal; BT¼ bitemporal; EEG¼ electroencephalogram; RUL ¼ right unilateral.
Ment Health Clin [Internet]. 2021;11(1):23-6. DOI: 10.9740/mhc.2021.01.023 24
resumed. After the 10th treatment, the patient sustained
resolution of depressive symptoms, denying insomnia,
anhedonia, and suicidal thoughts.
Discussion
It is not clearly understood how AEDs affect ECT response,
and there is no consensus on AED management. Although
several studies report successful ECT with AEDs,6-8 no
reports are available for the management of levetiracetam
combined with zonisamide during ECT. We implemented a
careful administration schedule for our patient’s AEDs
based on their pharmacokinetic properties, balancing the
goals of seizure prevention with ECT response. It was of
high importance to obtain rapid depression improvement,
and given our patient’s seizure-free duration prior to
admission, antiepileptic medications were reduced with
input from neurology. Our patient had adequate seizures
during ECT with no restimulations required and no
breakthrough seizures once ECT was initiated.
Zonisamide was discontinued 2 days prior to ECT
initiation and resumed after acute ECT series completion.
Zonisamide achieves peak concentrations 2 to 6 hours
after administration and reaches concentration steady-
state in approximately 2 weeks.9 In an effort to reduce
seizure occurrence when not being administered ECT and
also allow for quicker AED elimination on nights prior to
ECT, levetiracetam was switched from the XR formulation
to a higher dose of the IR formulation. Levetiracetam XR
peak plasma concentrations occurs after 4 hours with
peak time being 3 hours longer than the IR formulation.
The elimination half-life of levetiracetam is 9 hours in the
elderly with comparable bioavailability between the XR
and IR formulations.10 Given its elimination half-life,
zonisamide would likely have had detectable serum
concentrations during this patient’s course of treatment,
yet it did not prevent adequate seizure duration during
ECT. Similarly, we did not see adverse impacts on
treatment response or occurrence of breakthrough seizure
from the increased levetiracetam IR dose prescribed.
There is debate regarding the optimal anesthetic agent to
be used during ECT.11 Although etomidate monotherapy
or adding ramifentanyl to lower doses of methohexital for
anesthesia induction if inadequate seizures occur during
ECT can be considered,5 we continued our current practice
of using the barbituric acid derivative, methohexital, as an
inducing agent and altered the AEDs as described
previously. One randomized, double-blind, crossover
trial12 compared etomidate, methohexital, and propofol
as inducing agents for ECT in 10 patients with MDD;
however, none of these patients had seizure disorders or
took AEDs. Briefly, EEG seizures were longest after
etomidate induction and shortest with propofol, and the
clinical meaningfulness of this effect was not assessed.12
Etomidate had no dose-related differences in EEG seizure
duration although higher weight-based doses of metho-
hexital and propofol reduced seizure duration. Cognitive
recovery was longer in patients with longer seizure
duration, and discharge time from recovery room was 5
to 7 minutes longer with etomidate compared with other
agents.12 A meta-analysis, including open-label trials and
case series, found etomidate EEG seizure duration to be
2.23 seconds (95% CI¼ –3.62, 8.01; P¼.456) longer than
methohexital.12 Based on this data, etomidate as an
inducing agent does not clearly offer an advantage in
patients with epilepsy taking AEDs but could be
considered.
Our use of low-dose lorazepam with brief washout periods
the night prior to ECT procedures also appeared to have
little impact on bitemporal ECT effectiveness. Data
suggest BZDs decrease the efficacy of unilateral ECT13,14
but perhaps not during bilateral ECT. Retrospective data
suggest patients receiving BZDs had higher depression
remission rates than those not receiving BZDs (81.8% vs
52%, P¼.017) during primarily bilateral ECT.3 Another
retrospective study found patients with monopolar
depression who received an average of 17.95 mg (SD
20.3) diazepam equivalents had a response rate of 98.9%
and a remission rate of 90% with bitemporal ECT.15
Our case demonstrates that bilateral ECT effectiveness
was not compromised with the use of low-dose loraze-
pam, levetiracetam, and lack of complete zonisamide
elimination prior to the procedure. Limitations to our case
include that it represents a single patient, AED and BZD
serum concentrations were not monitored, and no
standardized depression rating scales were utilized.
Although our management of this case appears promising
for successfully continuing lorazepam, levetiracetam, and
zonisamide during ECT, more research and case reports
are necessary to recommend safe and effective utilization
of AEDs and BZDs during ECT.
Conclusion
Management of AEDs and BZDs during ECT poses
challenges, especially in patients with seizure disorders.
Valproate, carbamazepine, and lamotrigine have been
successfully continued during ECT in patients without
epilepsy,6-8 and a large case series supports AED
continuation in most patients with epilepsy receiving
ECT.4 BZDs do not usually impact ECT effectiveness when
the dose is held the morning prior to bilateral ECT
procedures.3,15 Our case suggests that utilizing the IR
formulation of levetiracetam, administering the evening
dose early the day prior to the procedure, and temporarily
discontinuing zonisamide dosing prior to bilateral ECT is
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effective for the treatment of severe MDD while
maintaining seizure prophylaxis.
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